Vitamin D and cancer mortality: what the VITAL extended follow-up shows

The VITAL trial reported in 2019 that 2,000 IU/day of vitamin D3 did not lower the incidence of invasive cancer in a generally vitamin-D-replete population. The headline read as a negative trial. Less attention went to a pre-specified secondary endpoint — cancer death — which trended favorably and continued to separate during extended follow-up. The current picture is less binary than the original press release suggested.

What VITAL actually tested

VITAL randomized 25,871 U.S. adults (men ≥50, women ≥55) without baseline cancer or cardiovascular disease to vitamin D3 2,000 IU/day, marine omega-3, both, or neither in a 2×2 factorial design [1]. Mean baseline 25-hydroxyvitamin D was 30.8 ng/mL — close to the U.S. average, which means the trial tested incremental supplementation, not deficiency correction. Median follow-up was 5.3 years for the primary report and extended to over 9 years in subsequent analyses.

The primary cancer incidence result

Total invasive cancer was 7.96% in vitamin D versus 7.96% in placebo — a flat null (HR 0.96, 95% CI 0.88–1.06). Subgroup analyses showed possible benefit in Black participants and those with normal BMI, but these were exploratory. The most-discussed finding was the absence of effect on incidence, leading many commentators to declare the cancer hypothesis closed [1].

The cancer mortality signal

Death from cancer was a pre-specified secondary endpoint. In the original 5.3-year analysis, vitamin D modestly reduced cancer death (HR 0.83, 95% CI 0.67–1.02), trending toward significance but not crossing the threshold. A pre-planned analysis excluding the first two years (to allow time for biologic effect) tightened the signal further (HR 0.75, 95% CI 0.59–0.96) [2]. Extended follow-up published in 2022 with 5.3 additional years of post-trial observation reported a sustained, statistically significant reduction in cancer mortality (HR 0.83, 95% CI 0.71–0.97) [3].

Why incidence and mortality might diverge

Vitamin D's preclinical mechanisms — antiproliferative effects, immune modulation, and inhibition of angiogenesis — are biologically more relevant to progression than to initiation. A drug that does not prevent tumor formation but slows growth in subclinical disease would produce exactly the pattern VITAL observed: flat incidence with reduced lethal cancer. Meta-analyses of multiple vitamin D trials report a 13% relative reduction in cancer mortality with surprisingly consistent point estimates across studies [4].

Where the evidence still falls short

VITAL did not enroll vitamin-D-deficient participants in meaningful numbers, so the inference applies to replete adults receiving incremental supplementation. The trial was not powered for specific cancer subtypes; signals in colorectal and digestive cancers exist in some pooled analyses but remain hypothesis-generating. Body-weight interaction is striking: in VITAL, the cancer mortality benefit was concentrated in normal-BMI participants, possibly because of dose dilution in larger adipose mass [5]. The FINGER and D-Health trials in slightly different populations showed neutral cancer mortality results, though both used dosing strategies that differ from VITAL's daily protocol [6].

How to interpret in 2026

For an average adult with a 25-hydroxyvitamin D level in the 20–30 ng/mL range, daily vitamin D3 supplementation of 1,000–2,000 IU is supported by multiple lines of evidence for skeletal outcomes, infection risk, and now — provisionally — cancer mortality. The signal does not justify chasing high serum levels above 50 ng/mL, where benefit plateaus and bolus-dose harm appears [7]. For the deficient (below 20 ng/mL), correction remains a clearer priority. For the cancer-prevention question specifically, VITAL's mortality finding is one of the more encouraging supplement readouts of the past decade, but it should not be oversold as a treatment claim.

The bottom line

VITAL did not show that vitamin D prevents cancer from arising. Its extended follow-up does show a small, durable reduction in cancer mortality with daily 2,000 IU supplementation. The effect is modest, possibly absent in obesity, and weakest where vitamin D status is already very high. For most adults, this finding adds to — rather than overturns — the case for routine, modest daily vitamin D supplementation, but it is not a justification for high-dose self-treatment of diagnosed cancer.